Evidence before scale.
One published study anchors our claims. Here is what it measured, what it found, where we fell short and what it cannot tell you.
Home blood collection for Memorial Sloan Kettering patients.
Memorial Sloan Kettering clinicians studied home phlebotomy delivered by myOnsite from 26 September 2022 to 31 December 2023, and published the results in JNCI Cancer Spectrum in 2024.
patients
home collection visits
specimens collected
hemolyzed specimens
Three benchmarks met. One target missed.
| Indicator | MSK benchmark | Result |
|---|---|---|
| Clotted specimens | 2% | 1 of 5,104 (0.02%) |
| Hemolyzed specimens | 1% | 0 of 5,104 (0%) |
| Mislabeled specimens | 0 | 0 of 5,104 |
| Collection to lab receipt | 120 minutes | 245 of 5,104 (4.80%) took longer |
Mislabeled
Mislabeled: 0
0 of 5,104 specimens. MSK benchmark: 0.
Unlabeled
Unlabeled: 1
1 of 5,104 specimens (0.02%). Reported by the paper separately from the four benchmarks above.
Source for both figures: Bange et al., JNCI Cancer Spectrum, 2024 (doi:10.1093/jncics/pkae104). Benchmarks were set in advance by MSK's Department of Pathology and Laboratory Medicine.
Four states.
These are the states where the study's visits took place. They are not a list of where myOnsite operates today. Current service coverage is shown separately below.
147 of 149 would use it again or recommend it.
Patients with a home visit between 26 September 2022 and 15 March 2023 were called with one yes-or-no question. Of 173 approached, 149 answered (86%), and 147 (99%) said yes.
Where myOnsite operates today.
This is current service coverage. It is separate from the four states where the published Memorial Sloan Kettering study took place.
myOnsite operates in 30 states as of October 2026. Coverage inside each state depends on the ZIP code.
Read these before the numbers.
- It took place at one comprehensive cancer center, including its regional network sites across four states.
- It used one mobile phlebotomy vendor, and quality may vary with vendor selection.
- It was a quality improvement study, run under an institutional review board waiver of consent.
Claims we do not make from it.
- Performance for draws from implanted ports
- Cost savings for the hospital or the patient
- Results for other cancer centers, other states or other vendors
Reference.
Bange EM, Bernal C, Gaffney KB, Ackerman J, Kwong D, Thomas J, Daly B. The feasibility and acceptability of home phlebotomy for patients with cancer. JNCI Cancer Spectrum. 2024;8(6):pkae104. doi:10.1093/jncics/pkae104
The authors are Memorial Sloan Kettering clinicians. Using the Memorial Sloan Kettering name or logo beyond this citation needs the institution's written permission. We cite the paper; we do not claim an endorsement.